Trospium

Trospium – Clinical Pharmacist–Focused Review

1. Drug Class

  • Antimuscarinic (anticholinergic)
  • Quaternary ammonium compound (important clinically)

2. Indication

  • Overactive bladder (OAB) with:
    • Urgency
    • Urge urinary incontinence
    • Frequency

3. Mechanism of Action (Clinical Perspective)

  • Competitive antagonist at muscarinic (M3 > M2) receptors in the bladder
  • ↓ detrusor muscle contractions
  • ↑ bladder capacity and ↓ urgency

Key Clinical Distinction

  • Being quaternary, trospium:
    • Is poorly lipid-soluble
    • Has minimal blood–brain barrier penetration
      → ↓ central anticholinergic effects compared with oxybutynin

4. Dosing (Adults)

Immediate-Release (IR)

  • 20 mg PO twice daily
  • Take at least 1 hour before meals or on an empty stomach

Extended-Release (ER)

  • 60 mg PO once daily
  • Morning, empty stomach

5. Renal Dose Adjustment (High-Yield)

Trospium is primarily renally eliminated unchanged.

Renal Function Recommendation
CrCl ≥30 mL/min No adjustment
CrCl <30 mL/min IR: 20 mg once daily at bedtime
ESRD / Dialysis Avoid or use with extreme caution
ER formulation Not recommended if CrCl <30 mL/min

Clinical Pearl: Trospium requires more renal caution than most other antimuscarinics.

6. Pharmacokinetics (Clinically Relevant)

Parameter Notes
Oral bioavailability ~10% (↓ further with food)
Protein binding Low
Metabolism Minimal hepatic metabolism
Elimination Renal (unchanged)
Half-life ~20 hours

7. Adverse Effects

Common (Anticholinergic)

  • Dry mouth
  • Constipation
  • Dyspepsia
  • Urinary retention

Less Common but Important

  • Blurred vision
  • Tachycardia
  • Cognitive effects (lower risk vs tertiary agents)

8. Cognitive & Geriatric Considerations

  • Lower CNS penetration → preferred in:
    • Older adults
    • Patients at risk of delirium or cognitive impairment

Still listed as potentially inappropriate in Beers Criteria due to anticholinergic burden—use lowest effective dose.

9. Contraindications

  • Urinary retention
  • Gastric retention
  • Uncontrolled narrow-angle glaucoma
  • Severe renal impairment (relative)

10. Drug Interactions (Practical)

  • Other anticholinergics → additive toxicity
  • Drugs eliminated by active tubular secretion (theoretical competition):
  • Food ↓ absorption significantly

11. Comparison Insight (Quick Clinical Context)

Feature Trospium
CNS effects ↓↓
Renal elimination High
Hepatic metabolism Minimal
Dry mouth Moderate
Preferred in elderly ✔ (with renal caution)

12. Counseling & Monitoring

  • Take on empty stomach
  • Monitor:
    • Post-void residual (high-risk patients)
    • Constipation
    • Cognitive changes
  • Reassess efficacy after 4–8 weeks

13. Clinical Pearls for Pharmacists

  • Good option when cognitive adverse effects are a concern
  • Avoid ER formulation in CrCl <30 mL/min
  • Less drug–drug interactions via CYP pathways
  • Consider β3-agonist (mirabegron) if anticholinergic burden is problematic

14. One-Line Summary

Trospium is a peripherally selective antimuscarinic for OAB with lower CNS toxicity, but its heavy renal elimination mandates careful dose adjustment in CKD.

Tags: